RCM
UNCY icon

RA Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

RA Capital Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-263,220
Closed -$1.32M – 85
2024
Q2 		$1.32M Sell
263,220
-83,849
-24% -$824K 0.02% 77
2024
Q1 		$4.79M Hold
347,069
– – 0.06% 75
2023
Q4 		$3.01M Hold
347,069
– – 0.05% 60
2023
Q3 		$2.98M Buy
+347,069
New +$3.25M 0.06% 63

Other funds holding UNCY

GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

RA Capital Management's UNCY Position: Q3 2024 in Review

RA Capital Management sold out of Unicycive Therapeutics (UNCY) in Q3 2024, closing a stake of 263,220 shares — an estimated $1.32M sold.

RA Capital Management first reported a position in UNCY in Q3 2023 and held it in 4 quarters. The position peaked at $4.79M in Q1 2024. 28 funds tracked by Wall St. Rank hold UNCY as of Q3 2024.

  • RA Capital Management reported no remaining Unicycive Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RA Capital Management sold 263,220 Unicycive Therapeutics shares in Q3 2024, an estimated $1.32M.
  • RA Capital Management first reported a position in Unicycive Therapeutics in Q3 2023 and held it in 4 quarters.
  • RA Capital Management's Unicycive Therapeutics position peaked at $4.79M in Q1 2024.
  • 28 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2024.

Based on RA Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.